Have a feature idea you'd love to see implemented?
Let us know!
SVRA Savara Inc
Price (delayed)
$3.24
Market cap
$556.05M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.43
Enterprise value
$561.17M
Savara is an orphan lung disease company. Its lead program, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Its management
Highlights
Savara's equity has soared by 96% from the previous quarter and by 36% YoY
SVRA's quick ratio has soared by 59% from the previous quarter but it is down by 9% YoY
SVRA's net income has plunged by 70% YoY and by 10% from the previous quarter
The company's EPS fell by 39% YoY and by 2.4% QoQ
Key stats
What are the main financial stats of SVRA
Market
Valuations
Earnings
Shares outstanding
171.62M
Market cap
$556.05M
Enterprise value
$561.17M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.68
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$81.42M
EBITDA
-$81.15M
Free cash flow
-$81.47M
Per share
Balance sheet
Liquidity
EPS
-$0.43
Free cash flow per share
-$0.38
Book value per share
$1.21
Revenue per share
$0
TBVPS
$1.13
Total assets
$238.82M
Total liabilities
$39.47M
Debt
$26.55M
Equity
$199.35M
Working capital
$213.61M
Debt to equity
0.13
Current ratio
17.7
Quick ratio
17.16
Net debt/EBITDA
-0.06
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-46.4%
Return on equity
-58.9%
Return on invested capital
-47.4%
Return on capital employed
-36%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SVRA stock price
How has the Savara stock price performed over time
Intraday
3.51%
1 week
1.57%
1 month
-9.24%
1 year
-13.14%
YTD
-31.06%
QTD
-23.58%
Financial performance
How have Savara's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$89.65M
Net income
-$82.94M
Gross margin
N/A
Net margin
N/A
SVRA's net income has plunged by 70% YoY and by 10% from the previous quarter
Savara's operating income has plunged by 68% YoY and by 10% from the previous quarter
Growth
What is Savara's growth rate over time
Valuation
What is Savara stock price valuation
P/E
N/A
P/B
2.68
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 39% YoY and by 2.4% QoQ
Savara's equity has soared by 96% from the previous quarter and by 36% YoY
The stock's price to book (P/B) is 44% less than its last 4 quarters average of 4.8 but 22% more than its 5-year quarterly average of 2.2
Efficiency
How efficient is Savara business performance
SVRA's return on assets is down by 35% year-on-year
SVRA's ROE is down by 33% YoY
Savara's ROIC has decreased by 26% YoY
Dividends
What is SVRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SVRA.
Financial health
How did Savara financials performed over time
The total assets has soared by 71% from the previous quarter and by 31% YoY
SVRA's quick ratio has soared by 59% from the previous quarter but it is down by 9% YoY
The debt is 87% smaller than the equity
Savara's equity has soared by 96% from the previous quarter and by 36% YoY
The debt to equity has plunged by 50% from the previous quarter and by 28% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.